Alpine Global Management’s Neurocrine Biosciences NBIX Stock Holding History

Alpine Global Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-7,765	Closed	-$661K	–	621
2021 Q4	$661K	Buy	+7,765	New	+$714K	0.1%	270
2020 Q1	–	Sell	-3,236	Closed	-$348K	–	368
2019 Q4	$348K	Buy	+3,236	New	+$339K	0.07%	239
2018 Q4	–	Sell	-2,619	Closed	-$322K	–	250
2018 Q3	$322K	Buy	+2,619	New	+$297K	0.06%	61
2014 Q4	–	Sell	-35,000	Closed	-$548K	–	615
2014 Q3	$548K	Sell	35,000 -65,000	-65%	-$971K	0.41%	61
2014 Q2	$1.48M	Buy	100,000 +77,105	+337%	+$1.09M	0.43%	41
2014 Q1	$369K	Buy	+22,895	New	+$392K	0.32%	66

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Alpine Global Management's NBIX Position: Q1 2022 in Review

Alpine Global Management sold out of Neurocrine Biosciences (NBIX) in Q1 2022, closing a stake of 7,765 shares — an estimated $661K sold.

Alpine Global Management first reported a position in NBIX in Q1 2014 and held it in 6 quarters. The position peaked at $1.48M in Q2 2014. 426 funds tracked by Wall St. Rank hold NBIX as of Q1 2022.

Alpine Global Management reported no remaining Neurocrine Biosciences position as of Q1 2022 after selling out during the quarter.
Alpine Global Management sold 7,765 Neurocrine Biosciences shares in Q1 2022, an estimated $661K.
Alpine Global Management first reported a position in Neurocrine Biosciences in Q1 2014 and held it in 6 quarters.
Alpine Global Management's Neurocrine Biosciences position peaked at $1.48M in Q2 2014.
426 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2022.

Based on Alpine Global Management's 13F filing for Q1 2022, filed 13 May 2022.